A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Aurora, Colorado +3 locations
Conditions: Neoplasms
Register for Updates
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
NCT00304070
Completed
This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or surgery works in treating young patients with stage I, stage II, stage III or stage IV adrenocortical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may make the tumor s... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/26/2024
Locations: Children's Hospital Colorado, Aurora, Colorado +1 locations
Conditions: Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
Register for Updates
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03661320
Active Not Recruiting
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Local Institution - 0021, Littleton, Colorado
Conditions: Muscle-Invasive Bladder Cancer, Urinary Bladder Neoplasms
Register for Updates
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
NCT03345784
Terminated
This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tu... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Cervical Carcinoma, Vaginal Carcinoma
Register for Updates
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
NCT03840902
Terminated
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: University of Colorado Health - Memorial Hospital - Memorial Hospital, Colorado Springs, Colorado +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
NCT05948462
Withdrawn
This clinical trial is an open-label, single arm study evaluating the safest dose of lorlatinib in combination with standard of care chemotherapy in participants with metastatic anaplastic lymphoma kinase positive (ALK+) NSCLC who progressed on prior therapy of lorlatinib alone. The main goals of this study are to: * Evaluate the safety and tolerability of lorlatinib in combination with standard of care chemotherapy. * Evaluate how well the combination of lorlatinib and standard of care chemoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Lung Cancer, Non-small Cell Lung Cancer
Register for Updates
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01004978
Completed
This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado +3 locations
Conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Register for Updates
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
NCT03684811
Completed
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas. The study is divided into two parts: single agent FT-2102 followed by combination therapy. Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Register for Updates
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
NCT03748134
Completed
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilim... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/22/2023
Locations: Rocky Mountain Cancer Centers, LLP, Denver, Colorado
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
NCT00942331
Completed
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2023
Locations: San Luis Valley Regional Medical Center, Alamosa, Colorado +48 locations
Conditions: Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Register for Updates
Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer
NCT04953962
Completed
Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21 days to patients with stage IV exocrine pancreatic cancer and WBC \< 10,000/mm3 at screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2023
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Pancreatic Cancer Stage IV
Register for Updates
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
NCT00047008
Completed
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways and combining it with chemotherapy before surgery may kill more tumor cells. It is not yet known which radiation therapy regimen combined with chemotherapy with or without surgery is more effective for head and neck cancer. PURPOSE: Randomized phase III trial to compare two different radiation therapy regimens combined with cisplatin with or without surgery in treating pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2023
Locations: Memorial Hospital Cancer Center, Colorado Springs, Colorado +1 locations
Conditions: Head and Neck Cancer
Register for Updates